SCHEMBL4067274

SCHEMBL4067274

Nc1snc2ncccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
HSP90AA1 P07900 4/20 0.38
HSP90AB1 P08238 3/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
BLM P54132 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ACHE P22303 2/20 0.38
NUDT1 P36639 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 1/20 0.36
IDO1 P14902 1/20 0.36
PSMB5 P28074 1/20 0.36
LIMK1 P53667 3/20 0.36
APAF1 O14727 1/20 0.35
TDP2 O95551 1/20 0.35
CASP3 P42574 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16417610 0.75 NPC1 (0.43) MAPTHSP90AA1LMNAMEN1KMT2A
SCHEMBL8805116 0.75 MAPT (0.38) MAPTHSP90AA1HSP90AB1LMNAMEN1
SCHEMBL12535507 0.71 LMNA (0.35) MAPTHSP90AA1LMNAKDM4ENUDT1
SCHEMBL15935214 0.71 NPC1 (0.35) MAPTHSP90AA1LMNAKMT2AHTT
SCHEMBL19957787 0.71 NPC1 (0.35) MAPTHSP90AA1HSP90AB1LMNAHTT
SCHEMBL15830162 0.71 NPC1 (0.35) MAPTHSP90AA1LMNAKDM4ELIMK1
SCHEMBL252078 0.67 NCF1 (0.56) MAPTHSP90AA1HSP90AB1LMNAMEN1
SCHEMBL29593164 0.67 NCF1 (0.56) MAPTHSP90AA1HSP90AB1LMNAMEN1
SCHEMBL4025561 0.67 KDM4E (0.45) MAPTLMNAKMT2AHTTHIF1A
SCHEMBL15652136 0.67 ADORA2A (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS EFFECTOR THERAPEUTICS, INC. 2017-05-25 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
EP-1772493-B1 AZO DYE FUJIFILM CORP (JP) 2016-07-20 EP disclosed
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 US disclosed
US-20090056038-A1 2-(cyano-),4-((6-methyl-),(7-(cyano-)isothiazolo(4,3-c)pyrid-3-yl)-azo-)phenol; vividcoloring; stability; radiation resistance; shampoo and sweat resistances; friction resistance; heat resistance; alkali resistance; oxidation color dyes; direct dyes; monoazo dyes KAO CORPORATION (JP) 2009-03-05 US disclosed
US-20090056038-A1 2-(cyano-),4-((6-methyl-),(7-(cyano-)isothiazolo(4,3-c)pyrid-3-yl)-azo-)phenol; vividcoloring; stability; radiation resistance; shampoo and sweat resistances; friction resistance; heat resistance; alkali resistance; oxidation color dyes; direct dyes; monoazo dyes KAO CORPORATION (JP) 2009-03-05 US disclosed
US-20080027221-A1 Azo Dye FUJIFILM CORPORATION (JP) 2008-01-31 US disclosed
US-20080027221-A1 Azo Dye FUJIFILM CORPORATION (JP) 2008-01-31 US disclosed
EP-1772493-A1 AZO DYE Fujifilm Corporation (JP) 2007-04-11 EP disclosed
EP-1381366-A4 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP disclosed
US-6825201-B2 ANTIVIRAL ACTIVITY; TREATMENT OF HIV AND AIDS BRISTOL-MYERS SQUIBB COMPANY 2004-11-30 US disclosed
EP-1381366-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-21 EP disclosed
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-05-22 US disclosed
WO-2002085301-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 470/4885HSP90AA1 1827/4885HSP90AB1 1352/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 501/4885HSP90AA1 2677/4885HSP90AB1 2097/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 470/4885HSP90AA1 1827/4885HSP90AB1 1352/4885
US-20090056038-A1 2-(cyano-),4-((6-methyl-),(7-(cyano-)isothiazolo(4,3-c)pyrid-3-yl)-azo-)phenol; vividcoloring; stability; radiation resistance; shampoo and sweat resistances; friction resistance; heat resistance; alkali resistance; oxidation color dyes; direct dyes; monoazo dyes SCO2, IK, AR MAPT 4174/4885HSP90AA1 525/4885HSP90AB1 581/4885
US-20080027221-A1 Azo Dye IK, ACMSD, ARG1 MAPT 4796/4885HSP90AA1 4373/4885HSP90AB1 4159/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885HSP90AA1 1768/4885HSP90AB1 1288/4885
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives IDO1, IDO2, INMT MAPT 2614/4885HSP90AA1 4771/4885HSP90AB1 4669/4885
US-20170145009-A1 HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS MAP3K9, MAP3K19, MAP3K20 MAPT 2303/4885HSP90AA1 3799/4885HSP90AB1 3339/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885HSP90AA1 1768/4885HSP90AB1 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.